Navigation Links
GeneLink Reports 2010 Results
Date:4/4/2011

ORLANDO, Fla., April 4, 2011 /PRNewswire/ -- GeneLink, Inc. (OTCBB: GNLK, "the Company," or "GeneLink"), a leading consumer genomics biotech company, today reported financial results for the fiscal year ended December 31, 2010.

Financial Highlights:

  • Gross margin increased from $4,906,710 in 2009 to $4,997,367 in 2010;
  • Annual net sales decreased 8.4%, $7,839,972 for 2010 as compared to $8,561,455 in 2009;
  • Operating losses in 2010 decreased to $2,169,898, a decrease of $292,329 from operating losses of 2009.  Excluding non-cash charges relating to the granting of stock, options and warrants, operating losses decreased $589,078 for 2010 as compared to 2009.

Dr. Bernard Kasten, GeneLink's Chairman and CEO stated, "The steps we took to improve our profit margins beginning in late 2009 and throughout 2010 have begun to show results.  Despite a decrease in revenue, gross margin improved $90,657 from $4,906,710 in 2009 to $4,997,367 in 2010. As a percent-of-revenue, the gross margins increased from 57% in 2009 to 64% in 2010.  This was largely due to improved pricing instituted late in 2009, as well as management's efforts to better control costs related to production.  These enhanced fundamentals bode well for the future financial success of GeneLink, as the Company expects to return to growth in the second half of 2011 through channel partner expansion as well as through growth in GeneWize."

Dr. Kasten added: "2010 was an important year from GeneLink.  We have put in place a large portion of the infrastructure necessary to expand our revenue base. The year-end agreement with Robert Trussell, founder of Tempur-pedic, Inc., to market GeneLink's proprietary products through his experienced direct response team is expected to commence producing revenue in the second half of 2011. GeneLink is now focused on our strengths in support of our channel partners:  cutting edge genetic research, reliable genetic testing, innovative and scientifically advanced product development, personalized manufacturing, protection of our intellectual property, and responsiveness to the developing regulatory environment.  I look forward to a very exciting 2011 for GeneLink and its shareholders."

About GeneLink Biosciences, Inc.:

GeneLink is a 17-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer's wellness needs. For more information visit www.genelinkbio.com

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
2. GeneLink Reports First Quarter Gains
3. GeneLink Announces HelixLife Private Label Distribution Agreement
4. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
5. GeneLink Reports Third Quarter Results
6. GeneLink Announces New Licensing Partner
7. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
8. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
9. Par Pharmaceutical Reports Second Quarter 2008 Results
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. Pharmos Corporation Reports 2008 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):